Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Consensus document on the use of granulocytapheresis in patients with inflammatory bowel disease].
Cabriada JL, Doménech E, Gomollón F, González-Carro P, González-Lara V, Hinojosa J, Jiménez-López CE, Nos P, Obrador A, Panès J, Saro C, Varea V, Lafuente R, Guilera M. Cabriada JL, et al. Among authors: saro c. Gastroenterol Hepatol. 2006 Feb;29(2):85-92. doi: 10.1157/13083905. Gastroenterol Hepatol. 2006. PMID: 16448611 Spanish. No abstract available.
Long-term durability of response to adalimumab in Crohn's disease.
Chaparro M, Panés J, García V, Merino O, Nos P, Domènech E, Peñalva M, García-Planella E, Esteve M, Hinojosa J, Andreu M, Muñoz F, Gutiérrez A, Mendoza JL, Barrio J, Barreiro-de M, Vera I, Vilar P, Cabriada JL, Montoro MA, Aldeguer X, Saro C, Gisbert JP. Chaparro M, et al. Among authors: saro c. Inflamm Bowel Dis. 2012 Apr;18(4):685-90. doi: 10.1002/ibd.21758. Epub 2011 May 25. Inflamm Bowel Dis. 2012. PMID: 21618353
Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial.
Hinojosa J, Gomollón F, García S, Bastida G, Cabriada JL, Saro C, Ceballos D, Peñate M, Gassull MA; Spanish Scientific Group on Crohn's Disease and Ulcerative Colitis. Hinojosa J, et al. Among authors: saro c. Aliment Pharmacol Ther. 2007 Feb 15;25(4):409-18. doi: 10.1111/j.1365-2036.2006.03232.x. Aliment Pharmacol Ther. 2007. PMID: 17269996 Free article. Clinical Trial.
Effectiveness of adalimumab in perianal fistulas in crohn's disease patients naive to anti-TNF therapy.
Castaño-Milla C, Chaparro M, Saro C, Barreiro-de Acosta M, García-Albert AM, Bujanda L, Martín-Arranz MD, Carpio D, Muñoz F, Manceñido N, García-Planella E, Piqueras M, Calvet X, Cabriada JL, Botella B, Bermejo F, Gisbert JP. Castaño-Milla C, et al. Among authors: saro c. J Clin Gastroenterol. 2015 Jan;49(1):34-40. doi: 10.1097/MCG.0000000000000169. J Clin Gastroenterol. 2015. PMID: 25485513
Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab.
Taxonera C, Estellés J, Fernández-Blanco I, Merino O, Marín-Jiménez I, Barreiro-de Acosta M, Saro C, García-Sánchez V, Gento E, Bastida G, Gisbert JP, Vera I, Martinez-Montiel P, Garcia-Morán S, Sánchez MC, Mendoza JL. Taxonera C, et al. Among authors: saro c. Aliment Pharmacol Ther. 2011 Feb;33(3):340-8. doi: 10.1111/j.1365-2036.2010.04531.x. Epub 2010 Dec 7. Aliment Pharmacol Ther. 2011. PMID: 21133961 Free article.
Outcomes of Medical and Surgical Therapy for Entero-urinary Fistulas in Crohn's Disease.
Taxonera C, Barreiro-de-Acosta M, Bastida G, Martinez-Gonzalez J, Merino O, García-Sánchez V, Gisbert JP, Marín-Jiménez I, López-Serrano P, Gómez-García M, Iglesias E, Lopez-Sanroman A, Chaparro M, Saro C, Bermejo F, Pérez-Carazo L, Plaza R, Olivares D, Alba C, Mendoza JL, Fernández-Blanco I. Taxonera C, et al. Among authors: saro c. J Crohns Colitis. 2016 Jun;10(6):657-62. doi: 10.1093/ecco-jcc/jjw016. Epub 2016 Jan 19. J Crohns Colitis. 2016. PMID: 26786982 Free article.
Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn's disease.
Aterido A, Palau N, Domènech E, Nos Mateu P, Gutiérrez A, Gomollón F, Mendoza JL, Garcia-Planella E, Barreiro-de Acosta M, Muñoz F, Vera M, Saro C, Esteve M, Andreu M, Chaparro M, Panés J, García-Sánchez V, López-Lasanta M, Pluma A, Codó L, García-Montero A, Manyé J, Gisbert JP, Marsal S, Julià A. Aterido A, et al. Among authors: saro c. Pharmacogenomics J. 2019 Dec;19(6):547-555. doi: 10.1038/s41397-019-0090-4. Epub 2019 May 2. Pharmacogenomics J. 2019. PMID: 31043678
Effectiveness of anti-TNFα drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNFα agent.
R-Grau Mdel C, Chaparro M, Mesonero F, Barreiro-de Acosta M, Castro L, Castro M, Domènech E, Mancenido N, Pérez-Calle JL, Taxonera C, Barrio J, De Francisco R, Fernández-Salgado E, Luzón L, Merino O, Oltra L, Saro C, Bermejo F, García-Sánchez V, Ginard D, Gutiérrez A, Vera I, Antón R, Ber Y, Calvet X, Gisbert JP. R-Grau Mdel C, et al. Among authors: saro c. Dig Liver Dis. 2016 Jun;48(6):613-9. doi: 10.1016/j.dld.2016.02.012. Epub 2016 Mar 2. Dig Liver Dis. 2016. PMID: 26992847
A genome-wide association study on a southern European population identifies a new Crohn's disease susceptibility locus at RBX1-EP300.
Julià A, Domènech E, Ricart E, Tortosa R, García-Sánchez V, Gisbert JP, Nos Mateu P, Gutiérrez A, Gomollón F, Mendoza JL, Garcia-Planella E, Barreiro-de Acosta M, Muñoz F, Vera M, Saro C, Esteve M, Andreu M, Alonso A, López-Lasanta M, Codó L, Gelpí JL, García-Montero AC, Bertranpetit J, Absher D, Panés J, Marsal S. Julià A, et al. Among authors: saro c. Gut. 2013 Oct;62(10):1440-5. doi: 10.1136/gutjnl-2012-302865. Epub 2012 Aug 30. Gut. 2013. PMID: 22936669
66 results